Jung-Ho Kim

CSO and acting CBO at Digmbio Inc

Speaker

Jung-Ho Kim is a Chief Scientific Officer and acting CBO, leading new drug discovery and development at DigmBio Inc. He is renowned for his pivotal role in developing and out-licensing Lazertinib to Yuhan during his tenure as CSO at Oscotec, alongside his colleagues. Lazertinib (Lazcluze) was finally licensed to Janssen, a pharmaceutical company of Johnson and Johnson, with FDA approval last year after the completion of the global phase 3 clinical trial, Mariposa, targeting non-small cell lung cancer treatment.
With extensive expertise in discovering and developing kinase inhibitors like Cevidoplenib, Denfivontinib, and Lazertinib while at Oscotec, Jung-Ho Kim has made significant contributions to the field and demonstrated exceptional leadership. He earned his Ph.D. in chemistry from the University of Illinois at Urbana-Champaign and completed his postdoctoral fellowship at Stanford University.